- Home
- CNF vs RAPT Comparison
CNF vs RAPT Comparison
Compare CNF & RAPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNF
- RAPT
- Stock Information
- Founded
- CNF 1999
- RAPT 2015
- Country
- CNF China
- RAPT United States
- Employees
- CNF N/A
- RAPT N/A
- Industry
- CNF Finance: Consumer Services
- RAPT Biotechnology: Pharmaceutical Preparations
- Sector
- CNF Finance
- RAPT Health Care
- Exchange
- CNF Nasdaq
- RAPT Nasdaq
- Market Cap
- CNF 59.0M
- RAPT 59.1M
- IPO Year
- CNF 2018
- RAPT 2019
- Fundamental
- Price
- CNF $1.12
- RAPT $1.25
- Analyst Decision
- CNF
- RAPT Hold
- Analyst Count
- CNF 0
- RAPT 10
- Target Price
- CNF N/A
- RAPT $6.00
- AVG Volume (30 Days)
- CNF 22.5K
- RAPT 627.1K
- Earning Date
- CNF 03-27-2025
- RAPT 03-06-2025
- Dividend Yield
- CNF N/A
- RAPT N/A
- EPS Growth
- CNF N/A
- RAPT N/A
- EPS
- CNF 0.24
- RAPT N/A
- Revenue
- CNF $109,788,152.00
- RAPT N/A
- Revenue This Year
- CNF N/A
- RAPT N/A
- Revenue Next Year
- CNF $13.09
- RAPT N/A
- P/E Ratio
- CNF $4.67
- RAPT N/A
- Revenue Growth
- CNF 12.99
- RAPT N/A
- 52 Week Low
- CNF $0.81
- RAPT $0.79
- 52 Week High
- CNF $2.84
- RAPT $10.05
- Technical
- Relative Strength Index (RSI)
- CNF 47.25
- RAPT 53.72
- Support Level
- CNF $1.07
- RAPT $1.10
- Resistance Level
- CNF $1.23
- RAPT $1.30
- Average True Range (ATR)
- CNF 0.09
- RAPT 0.09
- MACD
- CNF -0.02
- RAPT 0.02
- Stochastic Oscillator
- CNF 20.87
- RAPT 72.00
About CNF CNFinance Holdings Limited each representing twenty (20)
CNFinance Holdings Ltd is an equity loan service provider. It focuses on the development of small and micro-enterprises. It generates revenue in the form of interest and financing service fees on loans and interest on deposits with banks. Its primary target borrower segment is MSE owners who own real properties in Tier 1 and Tier 2 cities in China. Geographically, it has an operation in PRC.
About RAPT RAPT Therapeutics Inc.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.